Research/art/teacher profile of a person
Name and surname:
prof. MUDr. Danka Švecová, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Švecová
I.2 - Name
Danka
I.3 - Degrees
University Professor, M.D, PhD.
I.4 - Year of birth
1953
I.5 - Name of the workplace
Department of Dermatovenerology Faculty of Medicine, Comenius University
I.6 - Address of the workplace
Dekanát LFUK, Špitálska ulica 24, 813 72 Bratislava
I.7 - Position
University teacher - University professor
I.8 - E-mail address
danka.svecova@fmed.uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/3387/
I.10 - Name of the study field in which a person works at the university
Dermatovenerology
I.11 - ORCID iD
0000-0002-5096-1251

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Faculty of Medicine Comenius University in Bratislava
II.b - Year
1979
II.c - Study field and programme
General Medicine
II.3 - Third degree of higher education
II.a - Name of the university or institution
Faculty of Medicine Comenius University in Bratislava
II.b - Year
1989
II.c - Study field and programme
Candidatus of scientiarum "CSc", 51-14-9 Dermatovenerology, 1997 assigned as Philosophiae doctor "PhD"
II.4 - Associate professor
II.a - Name of the university or institution
Faculty of Medicine Comenius University in Bratislava
II.b - Year
2002
II.c - Study field and programme
Dermatovenerology
II.5 - Professor
II.a - Name of the university or institution
Faculty of Medicine Comenius University in Bratislava
II.b - Year
2014
II.c - Study field and programme
Dermatovenerology
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
University teacher- Assistant Professor- Assistant specialist Professor- Associate Professor - University Professor Faculty of Medicine Comenius University in Bratislava 1979 - continue
Professor of Dermatology University Hospital Old Town of Comenius University in Bratislava 1979- continue

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
Specialization of second degree Dermatology Institute of Further Education of Physicians and Pharmacists in Prague, Czech Republic 1991
Specialization of first degree Dermatology Institute of Further Education of Physicians and Pharmacists in Bratislava, Slovak Republic 1982
Study stay in Dermatology "Skin and Allergy" Hokkaido University School of Medicine, Sapporo, Japan 1996
Study stay in Dermatovenerology for Specialization of second Degree Institute of Further Education of Physicians and Pharmacists in Prague, Czech Republic 1991
Royal Holloway University of London, U.K. The International Conference on Harmonisation - Good Clinical Practice Guide Course 2014
The Investigator Site personnel ICH GCP Training Certtificate - Good Clinical Practice Transcelerate Biopharma, Inc, Pennsylvania, USA 2018
European computer driver licence Start-up, sylabus version: 4.0 2008 Comenius University in Bratislava 2008
Microsoft Innovative Educator: Command Expert of the TEAMS Comenius University in Bratislava 2020
Microsoft Innovative Educator: Command Expert of the PowerPoint Comenius University in Bratislava 2023

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Dermatovenerology 1+2 in slovak and english languages. Course ID: LF.DK/L-S-VL-008/19 General Medicine I. II General Medicine
Dermatovenerology in slovak and english languages. Course ID: LF.DK/L-ZLa-018/20 Dentistry I. II. Dentistry
Completition of the compulsory subject "New Trends in Dermatovenerology". Course ID: LF/L-PhD-007/22 General Medicine III. General Medicine
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.2.a - Name of the study programme V.2.b - Degree V.2.c - Field of study
Dermatovenerology. Specialization study III. General Medicine
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
4
V.4.c - Dissertation (third degree)
0
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
24
V.4.c - Dissertation (third degree)
5
V.5 - Overview of other courses taught in the current academic year according to study programmes

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
328
VI.1.b - Over the last six years
18
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
54
VI.1.b - Over the last six years
9
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
377
VI.1.b - Over the last six years
155
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
310
VI.1.b - Over the last six years
155
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
7
VI.1.b - Over the last six years
3
VI.2 - The most significant research/artistic/other outputs
1

Švecová D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger J. A randomized, double-blind, placebo-controlled phase I study of mutiple ascending doses of subcutaneous M1095, an anti-interleukin 17 A/F nanobody, in moderate-to-severe psoriasis. Journal of American Academy of Dermatology. 2019; 81:196-203. (Q1, IF=8.277)

2

Javor J, Chmúová N, Parnická Z, Ferenčík S, Grosse-Wilde H, Buc M, Švecová D.

TNF-alpha and IL-10 gene polymorphisms show a weak association with pemphigus vulgarisin the Slovak population. Journal of European Academy of Dermatology and Venereology. 2010;24:65-68. (Q1, IF=3.309)

3

Sochorova R, Švecova D, Sinka L, Rybarova L.

Increased endothelemia as an indirect marker of changes in the blood vessel endothelium in psoriasis. Journal of European Academy of Dermatology annd Venereology 2004; 18 (5): 556-559 (Q2, IF=1,401).

4

Švecová D. Pemphigus vulgaris: a clinical study of 44 cases over a 20-year period.International Journal of Dermatology. 2015; 54:1138-1144.(Q3, IF=1.415)

5

Švecová D, Párnická Z, Pastyriková L, Urbanček S, Luha J, Buc M.

HLA DRB1* and DQB1* alleles are associated with disease severity in patients with pemphigus vulgaris. International Journal of Dermatology. 2015; 54:168-173. (Q3, IF=1.415).

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Švecová D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger J. A randomized, double-blind, placebo-controlled phase I study of mutiple ascending doses of subcutaneous M1095, an anti-interleukin 17 A/F nanobody, in moderate-to-severe psoriasis. Journal of American Academy of Dermatology. 2019; 81:196-203. (Q1, IF=8.277)

2

Svecová D, Nemsovska J, Babal P. Clinical manifestation variability of bullous pemphigoid. Bratislava Medical Journal 2024; 125 (11):685-692. (Q2, IF 1.5).

3

Nemšovská J, Waczulíková I, Švecová D.Basophil activation in the diagnostics of hymmenoptera venon allergy. Bratislava Medical Journal 2021;122 (11):778-784. (Q2, IF 1.564).

4

Paul C, Stratigos Aj, Nijsten T et al. Author members: Svecova D et al. The "Buder of skin diseases" project: a population-based study on 44,689 Participants from 27 European countries. Minerva Medica. 2025; 116(1):81-83. (Q1, IF=4,7).

5

Švecová D. Pemphigus vulgaris: a clinical study of 44 cases over a 20-year period.International Journal of Dermatology. 2015; 54:1138-1144.(Q3, IF=1.415)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlelled , phase 2b study. The Lancet, 2021; 397:1564-1575 (Q1, IF=79,321).

2

Cheng L, Zhang X, Chen Y et all. Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Signal Trasduction and Targeted Therapy. 2021;6:304.(Q1, F=18,187).

3

Prinz I, Sandrock I, Mrowietz U. Effectors and targets in psoriasis - a breakthrough in understanding and treatment. Journal of Experimental Medicine. 2020; 217: e20191397 (Q1, IF=14,307).

4

Strober B, Carle P, Andrew B et all. Bimekizumab efficacy and safet& in patients with moderate to severe plaque psoriasis: two year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Journal of the American Academy of Dermatology. 2023; 89(3):486-495. (Q1, IF=11.5)

5

Assaf S, Malki L, Mayer T et al. ST18 affects cell–cell adhesion in pemphigus vulgaris in a tumour necrosis factor‐α‐dependent fashion. British Journal of Dermatology. 2021; 184(6):1153-1160.(Q1, IF=11,113).

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

Clinical study a phase I: Multicentre, phase I, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics and efficacy of multiple ascending doses of subcutaneous MSB0010841 (anti-IL17A/F nanobody) in male and female subjects with moderate to severe psoriasis. EudraCT:2013-005436-18.

Principal Investigator and Principal European Coordinator.

Publication:

Švecová D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger J. A randomized, double-blind, placebo-controlled phase I study of mutiple ascending doses of subcutaneous M1095, an anti-interleukin 17 A/F nanobody, in moderate-to-severe psoriasis. Journal of American Academy of Dermatology 2019; 81:196-203. (Q1, IF=8,177).

2

Clinical study a phase I: A phase 1, double-blind randomized, placebo controlled, multi dose study to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous LY3361237 in participants with psoriasis. EudraCT:2019-003187-40.

Principal Inverstigator.

3

Clinical study a phase III: A phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of PF-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis. B7451029, IND 123554. EudraCT Number 2018-002573-21.

Principal Investigator.

Publication:

Bieber T, Simpson J, Siverberg D et al. JADE COMPARE Investigators : Svecova D et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. New England Journal of Medicine 2021;384: 1101-1012. (Q1, IF=74,699).

4

Clinical study a phase II/III: A phase 2/3, randomized, double-blinded, placebo-controlled, parallel-group study to investigate the efficacy and safety of efgartigimod PH20SC in adut participants with bullous pemphigoid. Protocol number ARGX-113-2009. IND:1555276. EudraCT: 2021-003087-27.

Principal Investigator.

5

VEGA 1/7359/20: Immunomodulatory and antiinflamatory efficacy of natural phenols. In cooperation with Faculty of Pharmacy Coemnius University in Bratislava.

Vice- Investigator.

Publication:

Hajnická V, Košťálová D, Švecová D, Sochorová R, Fuchsberger N, Tóth J. Effect of Mahonia aquifolium active compounds on interleukin-8 production in the human monocytic cell line THP-1. Planta Medica 2002; 68: 266-268. (Q1, IF=2,289)

6

Clinical study phase II/III: An Open-label Extension Study of ARGX-1132009 to Evaluate the long-term safety, tolerability of efgartigimod PH20 SC in adut participants with bullous pemphigoid. Protocol number ARGX-113-2010. EudraCT: 2021-003063-10.

Principal investigator

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
23rd Asia-pacific Dermatology Conference,Osaka, Japan, Organisation Committee member Conferenceserie.com., Delaware , USA October 26.- 28. 2017
7th International Conferecnce on Family medicine & Primary care, Paris, France, Organisation Committee member CEO, EuroSciCon, UK February 22. - 24. 2018
17th European Dermatology Congress, Paris, France, Organisation Committee member Conferenceseries.com, London, UK March 1. - 3. 2018

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Hokkaido Universirty School of Medicine Sapporo, Japan 8. July 1996 - 30. September 1996 Under the supervision of Professor Akira Ohkawara, Dermatology "Alergy and Skin"
Institute of Further Education of Physicians and Pharmacists in Prague, Czech Republic University Hospital Bulovka, Prague 8, Czech Republic 1. April 1991- 25. June 1991 Under the supervision of Associate professor Pavel Barták, CsC.

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

2023 - continue Co-garant for the Dizertation Doktorand Study in Dermatovenerology, Faculty of Medicine Comenius University in Bratislava

2012 - continue Member of the Committee for Dizertation Doktorand Study in Dermatovenerology, Faculty of Medicine Comenius University in Bratislava

2009 - continue Member of the Committee for Specialization in Dermatovenerology, Faculty of Medicine Comenius University in Bratislava

2009 - continue Member of the Committee for Specialization in Dermatovenerology, University of Pavel Jozef Šafarik, Košice

2005-2012- Member of the Committee for Dizertation Doktorand Study in Imunology, Faculty of Medicine Comenius University in Bratislava

2011- continue Member of the committee for the State Conclusive Exam for General Medicine in slovak and english languages,

Faculty of Medicine Comenius University in Bratislava

2011- Gold Award, e-poster, World Congress of Dermatology, Seoul, South Korea

2011- continue Rewiever of scientific publications in Current Content Journals: Journal of European Academy of Dermatology and Venereology, International Journal of Dermatology,Journal of Immunology Research, Hindawi Portfolio of Journals, Archives of Dermatological Research (Springer Nature), Scientific Reports (Springer Nature), Bratislava Medical Journal (Springer Nature)

Date of last update
2025-04-23